Clinical Trial: Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura

Brief Summary: This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive Hetrombopag.

Detailed Summary:
Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Current Primary Outcome: The number of subjects with adverse events as a measure of safety and tolerability. [ Time Frame: From Day 1 to Day 70. ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Jiangsu HengRui Medicine Co., Ltd.

Dates:
Date Received: November 19, 2015
Date Started: August 2015
Date Completion:
Last Updated: November 22, 2015
Last Verified: November 2015